About Tectonic-1
Tectonic-1 (TCTN1) is a protein
from Homo sapiens identified by UniProt accession
Q2MV58, 587 residues long.
MolForge cross-references it against 0 known binders and
152 disease associations.
Target properties
| Protein name | Tectonic-1 |
| UniProt accession | Q2MV58 |
| Gene | TCTN1 |
| Organism | Homo sapiens |
| Length | 587 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (152)
Diseases linked to this target (Open Targets).
- Joubert syndrome · score 0.75
- Meckel syndrome · score 0.65
- Joubert syndrome and related disorders · score 0.62
- Global developmental delay · score 0.26
- genetic disorder · score 0.19
- schizophrenia · score 0.11
- autism spectrum disorder · score 0.09
- anorexia nervosa · score 0.09
- intelligence · score 0.08
- oral squamous cell carcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q2MV58-F1 | alphafold | PREDICTED | 77.57 | — |
Amino-acid sequence (587 residues)
MRPRGLPPLL VVLLGCWASV SAQTDATPAV TTEGLNSTEA ALATFGTFPS TRPPGTPRAP GPSSGPRPTP VTDVAVLCVC DLSPAQCDIN CCCDPDCSSV DFSVFSACSV PVVTGDSQFC SQKAVIYSLN FTANPPQRVF ELVDQINPSI FCIHITNYKP ALSFINPEVP DENNFDTLMK TSDGFTLNAE SYVSFTTKLD IPTAAKYEYG VPLQTSDSFL RFPSSLTSSL CTDNNPAAFL VNQAVKCTRK INLEQCEEIE ALSMAFYSSP EILRVPDSRK KVPITVQSIV IQSLNKTLTR REDTDVLQPT LVNAGHFSLC VNVVLEVKYS LTYTDAGEVT KADLSFVLGT VSSVVVPLQQ KFEIHFLQEN TQPVPLSGNP GYVVGLPLAA GFQPHKGSGI IQTTNRYGQL TILHSTTEQD CLALEGVRTP VLFGYTMQSG CKLRLTGALP CQLVAQKVKS LLWGQGFPDY VAPFGNSQAQ DMLDWVPIHF ITQSFNRKDS CQLPGALVIE VKWTKYGSLL NPQAKIVNVT ANLISSSFPE ANSGNERTIL ISTAVTFVDV SAPAEAGFRA PPAINARLPF NFFFPFV
Explore Tectonic-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets